articleClinical Cancer ResearchFeb 29, 2012BRONZE OA

Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma

JMJosep M. LlovetCECarol E. PeñaCLChetan LathiaMSMichael ShanGMGerold Meinhardt

Institució Catalana de Recerca i Estudis Avançats · Consorci Institut D'Investigacions Biomediques August Pi I Sunyer · +2 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Results

In both the entire patient population and the placebo cohort, baseline angiopoietin 2 (Ang2) and VEGF concentrations independently predicted survival. Clinical variables such as macroscopic vascular invasion, Eastern Cooperative Oncology Group (ECOG) performance status, and baseline α-fetoprotein and alkaline phosphatase concentrations also independently predicted survival in these groups. In the sorafenib cohort, trends toward enhanced survival benefit from sorafenib were observed in patients with high s-c-KIT or low hepatocyte growth factor concentration at baseline (P of interaction = 0.081 and 0.073, respectively).

Conclusions

The angiogenesis biomarkers Ang2 and VEGF were independent predictors of survival in patients with advanced HCC. In contrast, none of the biomarkers tested significantly predicted response to sorafenib.

Citation impact

561
total citations
FWCI
27.30
Percentile
100%
References
53
Citations per year

Authors

6

Topics & keywords

Topics
Keywords
  • Sorafenib
  • Medicine
  • Hepatocellular carcinoma
  • Internal medicine
  • Oncology
  • Placebo
  • Cohort
  • Population
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding